Unknown

Dataset Information

0

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.


ABSTRACT: Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human hematopoietic stem cells. We analyzed deep-coverage, targeted, next-generation sequencing (NGS) data of paired tumor and blood samples from 8,810 individuals to assess the frequency and clinical relevance of CH in patients with non-hematologic malignancies. We identified CH in 25% of cancer patients, with 4.5% harboring presumptive leukemia driver mutations (CH-PD). CH was associated with increased age, prior radiation therapy, and tobacco use. PPM1D and TP53 mutations were associated with prior exposure to chemotherapy. CH and CH-PD led to an increased incidence of subsequent hematologic cancers, and CH-PD was associated with shorter patient survival. These data suggest that CH occurs in an age-dependent manner and that specific perturbations can enhance fitness of clonal hematopoietic stem cells, which can impact outcome through progression to hematologic malignancies and through cell-non-autonomous effects on solid tumor biology.

SUBMITTER: Coombs CC 

PROVIDER: S-EPMC5591073 | biostudies-literature | 2017 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes.

Coombs Catherine C CC   Zehir Ahmet A   Devlin Sean M SM   Kishtagari Ashwin A   Syed Aijazuddin A   Jonsson Philip P   Hyman David M DM   Solit David B DB   Robson Mark E ME   Baselga José J   Arcila Maria E ME   Ladanyi Marc M   Tallman Martin S MS   Levine Ross L RL   Berger Michael F MF  

Cell stem cell 20170810 3


Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human hematopoietic stem cells. We analyzed deep-coverage, targeted, next-generation sequencing (NGS) data of paired tumor and blood samples from 8,810 individuals to assess the frequency and clinical relevance of CH in patients with non-hematologic malignancies. We identified CH in 25% of cancer patients, with 4.5% harboring presumptive leukemia driver mutations (CH-P  ...[more]

Similar Datasets

| S-EPMC4306669 | biostudies-literature
| S-EPMC7293239 | biostudies-literature
| S-EPMC8160503 | biostudies-literature
| S-EPMC10249057 | biostudies-literature
| S-EPMC8814311 | biostudies-literature
| S-EPMC6194804 | biostudies-literature
| S-EPMC9896303 | biostudies-literature
| S-EPMC7690564 | biostudies-literature
| S-EPMC7065480 | biostudies-literature